Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DRI Capital To Pursue Phase III Assets With Some Of Its Third Royalty Fund

This article was originally published in The Pink Sheet Daily

Executive Summary

Toronto-based health care royalty acquirer raises a $1.45 billion third fund, which it says should last between three-and-a-half and five years. It is mainly sticking with its prior investment strategy, although for the first time DRI will look at acquiring royalty rights to promising Phase III candidates.

You may also be interested in...



Financings Of The Fortnight: Is Google/Calico The Start Of A Wave Of Funding Alternatives?

As survey respondents broadly expect venture capital activity to wane in the coming years, are Google and their like pointing to the next way of financing life sciences innovation? Plus news on recent financings by Civitas Therapeutics, DRI Capital, Five Prime Therapeutics and Cubist Pharmaceuticals.

Capital Royalty To Offer Debt With New $1 Billion Fund

As the royalty field grows more crowded, the health care investor is turning away from passive royalties, the core strategy of its first fund, to become a lender to companies with products on the market or already approved.

Health And Wellness Weekly Trademarks Review: 28 June

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Topics

Related Companies

Related Deals

Latest News
UsernamePublicRestriction

Register

PS076347

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel